Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide.

Author(s) Ridolo, E.; Pellicelli, I.; Gritti, B.; Incorvaia, C.
Journal Patient Prefer Adherence
Date Published 2019
Abstract

Dual bronchodilation with long-acting beta-2 agonists and muscarinic antagonists is recommended in patients with severe to very severe COPD. Among dual bronchodilator combinations, indacaterol/glycopyrronium combination (IGC) received evidence of higher efficacy and good safety compared with monotherapy with either drug as well as with tiotropium. In randomized controlled trials, the primary outcome is usually the change in mean FEV resulting from treatment. However, the functional aspects that influence the physician's choice of the type of management may not be considered important by the patient, based on his perception of the disease. To address such issue, patient-reported outcomes (PROs) were assessed in recent studies. They include patient's perception of breathlessness, physical functioning, global health status, quality of life, use of rescue medications, and patient's report of COPD exacerbations. PRO data from the studies showed a clear improvement in patients' awareness of a better control of the disease in patients treated with IGC. In addition, the latest literature on two important issues influencing patient's preference and adherence, ie, the once-daily administration and the device to be used, confirmed the effectiveness of IGC and the ability of its device (Breezhaler) to result in patient's satisfaction, ease of use, less handling errors, and self-assurance to have inhaled the entire dose.

DOI 10.2147/PPA.S166704
ISSN 1177-889X
Citation Ridolo E, Pellicelli I, Gritti B, Incorvaia C. Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide. Patient Prefer Adherence. 2019;13:145-150.

Related Applications, Forms & Industries